SEC Form 4 reporting owner

Andrews Patricia S

Andrews Patricia S has filed 3 Form 4 transactions reported between February 12, 2026 and June 1, 2026, as Director of ONCOLYTICS BIOTECH INC and a reporting owner of GERON CORP.

Name as filed: Andrews Patricia S

Open-market buys, 24 mo
$30K
1 lines
Open-market sales, 24 mo
None
reported
Companies
2
with Form 4 filings
Latest transaction
Jun 1, 2026
transaction date

Roles and reported holdings

  • ONCYONCOLYTICS BIOTECH INC
    Feb 12, 2026 – Jun 1, 2026

    Director

    Held directly78,128 sh as of Feb 12, 2026 · Form 4

    24 months: $30K bought

  • GERNGERON CORP
    Mar 25, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 3 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 1, 2026ONCYDirectorGrant or awardCode A · direct30,000—Form 4
Mar 25, 2026GERNGrant or awardCode A · direct270,000—Form 4
Feb 12, 2026ONCYDirectorOpen-market purchaseCode P · direct35,400$30K@ $0.8557Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.